TTX-080 is a first-in-class monoclonal antibody targeting human leukocyte antigen G (HLA-G), acting by blocking the binding of HLA-G to its inhibitory receptors such as ILT2 and ILT4. The compound is an essential tool for investigating tumor immune escape mechanisms, aiming to restore the killing efficacy of immune cells against malignant tissues by lifting the HLA-G-mediated checkpoint signaling.
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
